Risperdal changeover tests J&J

Share this article:
Johnson & Johnson swung to a first-quarter loss as the company took a charge from an acquisition and felt the impact of challenges to some of its prescription drug and device franchises. First-quarter profit came in 22% less than last year’s, due to a charge for the acquisition of heart-device maker Conor Medsystems. The December acquisition of Pfizer’s consumer unit for $16.6 billion, though, helped boost sales 16%. J&J, the biggest seller of stents worldwide, said revenue from drug-coated stents like Cypher fell 27% to $530 million, following studies linking the devices to elevated risk of fatal blood clots. Pharmaceutical revenue rose 11% to $6.2 billion. But weak performers in the segment included anti-inflammatory drug Remicade, which grew just 7.3% to $731 million, according to The Wall Street Journal, versus double-digit growth in the year-ago period. Due to generics, sales of pain patch Duragesic dipped 6.8% to $303 million. Sales of anemia drug Procrit rose 2% to $817 million. US sales of anti-psychotics—including Risperdal, long-acting injectable Risperdal Consta and Invega—increased 16% to $1.2 billion, the conglomerate said. J&J didn’t release separate numbers for Invega, its Risperdal follow-on which launched in the US in January. But an analysis of first-quarter US sales growth by WSJ’s Health Blog, citing data from Wolters Kluwer, shows Invega sales of just $7.4 million—a slow start for a drug J&J is counting on to replace its top-selling medicine, Risperdal, which generated a 13% hike in sales from last year to $553 million and is set to face patent expiration in 2008. During an earnings call with analysts, J&J CFO Dominic Caruso said Invega is “tracking along to our expectations,” according to Thomson StreetEvents. That’s with a label indication for schizophrenia only; a bipolar mania filing is expected in 2008. Risperdal’s label includes both indications.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...